cxcl6  (R&D Systems)

Journal: bioRxiv

Article Title: Vascular endothelial growth factor-D improves lung vascular integrity during acute lung injury

doi: 10.1101/2024.12.16.628787

Figure Lengend Snippet: A, B) The electrical resistance and permeability in HLMVECs after treatment with VEGF-D (1 μg/mL), adrenomedullin (ADM)(100 ng/mL), angiopoietin 1 (ANGPT1)(2 μg/mL), BMP-5 (1 μg/mL), SLIT2 (1 μg/mL), CXCL6 (1 μg/mL), Pleiotrophin (PTN)(1 μg/mL), SEMA6D (1 μg/mL), and TNF-α (1 ng/mL) were measured through electrical cell impendence sensing (ECIS) assay, and transwell assay, respectively. C) HLMVECs cultured on transwell treated with VEGF-D, followed by challenging with IL1β, TNF-α, or thrombin. The permeability was determined using a 20kDa FITC-dextran probe. D) Immunofluorescent images of F actin (red), and VE-Cadherin (green) in HLMVECs challenged with TNF-α or IL1β with or without VEGF-D. White boxes highlight VE-Cadherin junctions in all conditions. Scale bar 20 μm. E) Protein expression of phosphor-MLC in HLMVECs challenged with thrombin with different concentrations of VEGF-D was assessed through a western blot. Data presented as mean ± SEM. * and ** indicate p<0.05 and p<0.01, respectively.

Article Snippet: The following ligands were purchased from vendors: BMP5 (Novus Biologicals, # 615-BMC-020), VEGF-D (Cayman Chemical, #32055), Adrenomedullin (ADM)(Cayman Chemical, #24889), Angiopoietin-1 (Novus Biologicals, #923-AN), TNF-α (R&D Systems, # 10291-TA), Slit homolog 2 (SLIT2)(R&D Systems, # 8616-SL), CXCL6 (R&D Systems, # 333-GC-025/CF), Pleiotrophin (PTN)(R&D Systems, # 252-PL), and Semaphorin 6D (Sema6D)(R&D Systems, #2095-S6).

Techniques: Permeability, Transwell Assay, Cell Culture, Expressing, Western Blot

Journal: The Journal of allergy and clinical immunology

Article Title: Positionally distinct interferon-stimulated dermal immune-acting fibroblasts promote neutrophil recruitment in Sweet syndrome

doi: 10.1016/j.jaci.2025.05.029

Figure Lengend Snippet: Interferon (IFN)-activated fibroblasts (FBs) are enriched in SS skin. A, Number of significantly upregulated genes (adjusted P value [ P adj ] < .05) in patients with SS versus patients with HC for each cell type. Differential expression analysis was performed using DESeq2. Pseudobulked data were used to control for cell number. B, Dimensionality reduction and unsupervised clustering of FBs, colored by subset. C, Expression of the top 4 marker genes per FB subset. D, Proportion of FB subsets for each condition. E, Pathway analysis inferring upstream transcription factors regulating gene expression for each cluster. F, Scaled expression of neutrophil chemokine CXCR2 ligands ( CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 , and CXCL8 ) and CXCR4 ligand ( CXCL12 ) across cell types for each condition. Keratinocytes, eccrine cells, and melanocytes were combined into the category epithelial. DCs, pDCs, mast cells, and myeloid cells were combined into the category myeloid. Plasma cells and lymphoid cells were combined into the category lymphoid. Vascular endothelial cells, lymphatic endothelial cells, and mural cells were combined into the category endothelial-mural. Proliferating cells and adipocytes were excluded. Error bars represent SEMs.

Article Snippet: The TaqMan primers included RPLP0 (Thermo Fisher Scientific; catalog no. Hs004200895_gh), CXCL1 (Thermo Fisher Scientific; catalog no. Hs00236937_m1), CXCL2 (Thermo Fisher Scientific; catalog no. Hs00234140_m1), CXCL3 (Thermo Fisher Scientific; catalog no. Hs00171061_m1), CXCL5 (Thermo Fisher Scientific; catalog no. Hs00982282_m1), CXCL6 (Thermo Fisher Scientific; catalog no. Hs00237017_m1), and CXCL8 (Thermo Fisher Scientific; catalog no. Hs00174103_m1).

Techniques: Quantitative Proteomics, Control, Expressing, Marker, Gene Expression, Clinical Proteomics